A examine released in JAMA Network Open up emphasizes the discrepancy amongst what it prices to produce copyright and the retail costs sufferers deal with. Regardless of the low generation fees, Novo Nordisk hasn't publicly disclosed specific figures for copyright or its other item, Wegovy.